Avid Bioservices Inc (CDMO, Financial) is set to release its Q1 2025 earnings on Sep 9, 2024. The consensus estimate for Q1 2025 revenue is $40.76 million, and the earnings are expected to come in at -$0.06 per share. The full year 2025's revenue is expected to be $162.83 million and the earnings are expected to be -$0.23 per share. More detailed estimate data can be found on the Estimates page.
Avid Bioservices Inc (CDMO, Financial) Estimates Trends
Revenue estimates for Avid Bioservices Inc (CDMO) have declined from $164 million to $162.83 million for the full year 2025 and from $201.1 million to $196.16 million for 2026 over the past 90 days. Earnings estimates for Avid Bioservices Inc (CDMO) have declined from -$0.19 per share to -$0.23 per share for the full year 2025 and from $0.18 per share to -$0.03 per share for 2026 over the past 90 days.
Avid Bioservices Inc (CDMO, Financial) Reported History
In the previous quarter of April 30, 2024, Avid Bioservices Inc's (CDMO) actual revenue was $42.98 million, which beat analysts' revenue expectations of $42.14 million by 1.98%. Avid Bioservices Inc's (CDMO) actual earnings were -$1.94 per share, which missed analysts' earnings expectations of -$0.04 per share by -5005.26%. After releasing the results, Avid Bioservices Inc (CDMO) was up by 14.93% in one day.
Avid Bioservices Inc (CDMO, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 4 analysts, the average target price for Avid Bioservices Inc (CDMO) is $12.50 with a high estimate of $16 and a low estimate of $8. The average target implies an upside of 38.89% from the current price of $9.
Based on GuruFocus estimates, the estimated GF Value for Avid Bioservices Inc (CDMO, Financial) in one year is $23.20, suggesting an upside of 157.78% from the current price of $9.
Based on the consensus recommendation from 5 brokerage firms, Avid Bioservices Inc's (CDMO, Financial) average brokerage recommendation is currently 2.0, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
